Last reviewed · How we verify

NCT04318470

Identification of Microbial DNA in Maternal Plasma After PPROM

Completed Last updated 7 April 2023
What this trial tests

trial testing mNGS in Preterm Rupture of Membranes in 70 participants. Completed in 31 December 2022.

Timeline
12 February 2020
Primary endpoint
31 December 2022
31 December 2022

Quick facts

Lead sponsorUniversity of California, San Francisco
StatusCompleted
Study typeOBSERVATIONAL
Enrollment70
Start date12 February 2020
Primary completion31 December 2022
Estimated completion31 December 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of California, San Francisco

Who can join

Adults 18 to 55, female only, with Preterm Rupture of Membranes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the use of metagenomic next generation sequencing in identifying microbial DNA in plasma samples of patients with preterm premature rupture of membranes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of mNGS

Trials testing the same drug.

Other University of California, San Francisco trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04318470.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing